Addyi Cardiovascular Impact Long-Term: What the Evidence Actually Shows

What Flibanserin Does to Blood Pressure and Heart Rate

Flibanserin lowers blood pressure acutely. In the FDA-reviewed pharmacodynamic studies submitted for the 2015 NDA, single 100 mg doses reduced mean systolic blood pressure by approximately 3 to 5 mmHg in healthy volunteers under alcohol-free conditions. [1] That number sounds modest, but it compounds dramatically with co-ingested alcohol or CYP3A4 inhibitors.

The mechanism is not a direct cardiac depressant effect. Flibanserin acts primarily as a serotonin 5-HT1A agonist and 5-HT2A antagonist, with secondary alpha-2 adrenergic agonist activity. [2] The alpha-2 component produces peripheral vasodilation and reduced sympathetic tone, which explains the orthostatic component of its hypotensive effect.

Syncope Incidence in Clinical Trials

Across the three key phase 3 trials (BEGONIA, DAISY, and VIOLET), syncope was reported in 0.4% of flibanserin-treated subjects versus 0.2% in placebo arms. [3] The absolute numbers are small, but the relative doubling in syncopal events drove the FDA's black-box warning. In BEGONIA specifically (N=949), the cardiovascular adverse event profile was consistent with this pattern, with hypotension and dizziness cited as the most common discontinuation-related adverse events in the active arm. [4]

Orthostatic Hypotension: The Real-World Signal

Orthostatic hypotension deserves separate attention from supine blood pressure changes. Because flibanserin is dosed at bedtime, a patient who wakes at night to use the bathroom faces the combined effect of drug peak plasma concentration (Tmax approximately 1 to 2 hours post-dose) and postural change. [1] This timing combination likely explains why fall-related injuries appear disproportionately in post-marketing case reports, even when formal trial syncope rates appear low.

The Alcohol Interaction: A Black-Box Warning Backed by Data

The FDA conducted a dedicated alcohol interaction study as part of the 2015 NDA review. Co-administration of flibanserin 100 mg with alcohol produced clinically significant hypotension in a proportion of participants large enough to halt enrollment early. [5]

What the Interaction Study Found

In that study, 25 subjects received flibanserin 100 mg with varying doses of alcohol (0.4 g/kg and 0.8 g/kg). Six of 23 evaluable subjects experienced hypotension meeting pre-specified criteria (systolic BP <90 mmHg or symptomatic), compared to none in the placebo-alcohol arm. Three subjects experienced syncope. [5] The FDA classified this interaction as severe and made alcohol avoidance a condition of REMS certification.

Clinical Implications for Prescribers

Patients do not always disclose alcohol use accurately. One strategy used at HealthRX: asking specifically about weekend and social drinking patterns rather than asking "do you drink," since the latter is more likely to elicit underreporting. The REMS program requires a patient-provider agreement form acknowledging alcohol abstinence, but behavioral compliance is not monitored biochemically in any published protocol.

A practical clinical framework for assessing flibanserin cardiovascular risk before prescribing:

1. Baseline orthostatic blood pressure check (supine to standing after 2 minutes).
2. Medication reconciliation focused on CYP3A4 inhibitors and CNS depressants.
3. Alcohol use quantification using AUDIT-C, with a score of 3 or higher prompting a shared decision-making conversation about REMS requirements.
4. Repeat orthostatic vitals at the 4-week follow-up visit, coinciding with the earliest point where steady-state CNS adaptation is measurable.
5. Explicit fall-risk counseling for patients aged 45 to 50 who may have early postural instability unrelated to flibanserin.

CYP3A4 Drug Interactions and Cardiovascular Amplification

Flibanserin is metabolized extensively by CYP3A4 and, to a lesser degree, CYP2C19. [2] Co-administration with moderate or strong CYP3A4 inhibitors can raise flibanserin plasma concentrations by 2- to 7-fold, directly amplifying the hypotensive risk.

Strong Inhibitors: Contraindicated

The FDA label lists the following as contraindicated: ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, and several other HIV protease inhibitors. [1] In a dedicated pharmacokinetic study, co-administration of fluconazole 200 mg (a moderate CYP3A4 inhibitor) with flibanserin 100 mg increased flibanserin AUC by approximately 7-fold. [6] That degree of exposure amplification carries a corresponding increase in cardiovascular depression risk.

Moderate Inhibitors: Prescribe with Caution

Moderate inhibitors including fluconazole, ciprofloxacin, and grapefruit juice require at least a 2-week washout before initiating flibanserin. [1] Grapefruit juice deserves specific mention because patients rarely consider it a drug interaction risk. A single 8 oz glass of double-strength grapefruit juice raised flibanserin Cmax by approximately 1.8-fold in the FDA interaction data. [6]

CYP2C19 Poor Metabolizers

Approximately 2 to 3% of Caucasian women and 15 to 20% of Asian women are CYP2C19 poor metabolizers. [7] In this subgroup, flibanserin clearance is reduced even in the absence of pharmacological inhibitors. Genotyping is not standard of care before flibanserin prescribing, but awareness of this pharmacogenomic variation is relevant when a patient reports unexpectedly strong sedative or hypotensive effects at standard dose.

What the BEGONIA Trial Tells Us About Cardiovascular Safety

BEGONIA (N=949) was a 24-week, double-blind, placebo-controlled phase 3 trial evaluating flibanserin 100 mg at bedtime in premenopausal women with HSDD. [4] The primary efficacy endpoints were satisfying sexual events (SSEs) and the Female Sexual Distress Scale-Revised (FSDS-R) score.

Cardiovascular Adverse Events in BEGONIA

From a cardiovascular standpoint, the trial reported the following in the flibanserin arm versus placebo: dizziness (11.4% vs. 2.3%), somnolence (10.7% vs. 3.8%), nausea (10.4% vs. 3.5%), and fatigue (8.5% vs. 3.4%). [4] None of these are primary cardiac endpoints, but dizziness and fatigue at these frequencies suggest a clinically meaningful degree of hemodynamic perturbation in daily life, not just in pharmacokinetic challenge studies.

Syncope was not separately reported in the published BEGONIA manuscript, likely because it was a rare event captured in the pooled safety database rather than in any single trial. The pooled safety database across all phase 2 and phase 3 trials included approximately 4,600 women, with a total exposure of roughly 2,100 person-years. [3]

What BEGONIA Did Not Measure

BEGONIA had no electrocardiographic endpoints. QTc interval data were not reported in the primary publication. The trial excluded women with cardiovascular disease, so the BEGONIA safety data apply specifically to generally healthy premenopausal women and cannot be extrapolated to women with structural heart disease, conduction abnormalities, or prior syncopal events. [4]

Long-Term Cardiovascular Data: What Exists and What Does Not

This is where the honest answer requires some candor. No published randomized controlled trial has evaluated flibanserin's cardiovascular safety beyond 24 weeks. [3] The FDA did not require a long-term cardiac outcomes trial as a condition of approval, in contrast to the approach taken for drugs like rosiglitazone (which received an FDA mandate for cardiovascular outcomes trials under a 2008 guidance). [8]

Post-Marketing Surveillance Gaps

The MedWatch database contains post-marketing adverse event reports for flibanserin since 2015, but these are voluntary and subject to reporting bias. As of publicly available FDA adverse event reporting system (FAERS) data, syncope and hypotension remain the most frequently reported cardiovascular adverse events. [9] No cases of myocardial infarction, ventricular arrhythmia, or stroke have been causally attributed to flibanserin in FAERS, though the denominator of total exposures is difficult to establish with precision.

QTc Interval: A Specific Question

The FDA thorough QT study for flibanserin showed no clinically meaningful QTc prolongation at the therapeutic dose of 100 mg. [1] At supratherapeutic doses (3-fold above therapeutic), mean QTcF change from baseline was less than 2 ms, well below the 10 ms threshold that triggers regulatory concern. [10] This finding effectively rules out flibanserin as a torsades de pointes risk at prescribed doses.

Chronic Blood Pressure Effects

Whether daily 100 mg dosing at bedtime produces measurable 24-hour blood pressure reduction over months of therapy has not been studied with ambulatory blood pressure monitoring in any published trial. Given the short half-life of flibanserin (approximately 11 hours), meaningful daytime blood pressure effects from a bedtime dose seem pharmacokinetically improbable, though not impossible in CYP3A4 poor metabolizers or those on inhibitors. [2]

Who Is at Highest Cardiovascular Risk on Flibanserin

Not all patients carry equal risk. The following clinical profiles warrant extra caution or alternative management.

High-Risk Profiles

Women with baseline orthostatic hypotension (defined as a systolic drop of 20 mmHg or more, or diastolic drop of 10 mmHg or more, on standing) have a mechanistically plausible reason for increased syncope risk on flibanserin. [11] This population was largely excluded from key trials.

Women taking antihypertensive medications represent a second high-risk group. No dedicated drug interaction study evaluated flibanserin co-administration with calcium channel blockers, ACE inhibitors, or diuretics. The FDA label does not list antihypertensives as contraindications but notes that additive blood pressure-lowering effects are possible. [1]

Women with structural heart disease, including those with hypertrophic obstructive cardiomyopathy or moderate aortic stenosis, may have reduced tolerance for acute reductions in preload. Syncopal thresholds are lower in these conditions. [12]

Age and Menopausal Status

Flibanserin is FDA-approved only for premenopausal women. Postmenopausal use is off-label and has not been studied systematically. Postmenopausal women have higher baseline rates of orthostatic hypotension and cardiovascular disease, which changes the risk-benefit calculation meaningfully. [13] The American College of Obstetricians and Gynecologists states in its 2019 committee opinion on female sexual dysfunction that "data are insufficient to recommend flibanserin for postmenopausal women." [14]

The REMS Program: Structure and Cardiovascular Rationale

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for flibanserin at approval, specifically because of the cardiovascular risk from the alcohol interaction. [5] The REMS requires:

• Prescriber certification after completing a training module.
• Pharmacy certification before dispensing.
• Patient enrollment and acknowledgment of the alcohol abstinence requirement.

As of 2023, the REMS program has been administered by Sprout Pharmaceuticals and its successor entities. The FDA's REMS database lists the current program status as active. [9]

Does the REMS Actually Reduce Cardiovascular Events?

No published study has evaluated whether REMS compliance reduces real-world syncope or hypotension rates compared to a pre-REMS baseline. This is a genuine evidence gap. The REMS creates a documentation trail but does not biochemically verify alcohol abstinence, and patient-reported adherence to abstinence requirements in any chronic medication context is typically lower than reported in clinical trials. [15]

Clinical Management: Monitoring and When to Stop

Routine cardiac monitoring (ECG, Holter) is not required for flibanserin prescribing. The FDA label specifies no mandatory laboratory or cardiac testing. [1] Clinically reasonable monitoring includes:

Pre-Treatment Assessment

Orthostatic vital signs at baseline. A full medication reconciliation with specific focus on CYP3A4 inhibitors, CNS depressants, and antihypertensives. Alcohol use screening with a validated tool such as AUDIT-C. Blood pressure below 90/60 mmHg at baseline is a practical reason to defer initiation pending further evaluation.

Follow-Up at 4 Weeks

At 4 weeks, reassess orthostatic vitals and ask directly about dizziness, near-syncope, or falls. If no efficacy signal is present (patient reports no meaningful change in FSDS-R or SSE frequency), the FDA label supports discontinuation at 8 weeks if the drug is not working, since benefit-risk favors stopping a drug with cardiovascular liability when it provides no clinical benefit. [1]

Absolute Stop Criteria

Any witnessed syncopal episode, any systolic blood pressure below 90 mmHg on repeat measurement, or any fall resulting in injury warrants immediate discontinuation and a focused cardiovascular evaluation. The FDA MedWatch program should be notified for any serious cardiovascular adverse event. [9]